Radiotherapy Halved Brain Cancer Recurrence Risk
A new clinical trial found that post-surgical radiotherapy significantly improved disease-free survival rates.
Updated on Sept. 25, 2026 in Cancer
Live Poll
Would you follow new study findings to guide your personal medical treatment decisions?
A study published in The Lancet revealed that daily radiotherapy following surgery for atypical meningioma cut recurrence rates by more than half. Patients undergoing the treatment showed higher five-year disease-free survival compared to those who only received active monitoring.
Why it matters
Atypical meningiomas are highly prone to returning within five years of initial surgery, making effective secondary treatment crucial for patient longevity. These findings offer a clear clinical pathway to reduce recurrence risk for a significant portion of brain tumor patients.
The study enrolled 157 patients, achieving an 80% five-year disease-free survival rate with radiotherapy versus 64% for the monitored group. Atypical meningiomas represent 27% of all diagnosed brain tumors.
The players
The Lancet
This is a peer-reviewed medical journal that publishes original research and findings on significant health topics.
Andy Tudor
He is a patient who participated in the medical process for atypical meningioma after being diagnosed in 2017.
The details
Researchers tracked 157 patients from 2016 to 2021, comparing those who received six weeks of daily radiotherapy against those who underwent only active monitoring. While the radiotherapy group reported short-term side effects like hair loss and headache, the reduction in tumor recurrence was marked.
Timeline
Patients were enrolled in the medical trial between 2016 and 2021.
Andy Tudor was diagnosed with atypical meningioma in 2017.
Andy Tudor experienced a tumor recurrence in January 2022.
Andy Tudor received stereotactic radiotherapy in March 2022.
The Big Picture
This study follows a pattern of clinical advancement established by The Lancet's neuro-oncology research publications.
Patients diagnosed with atypical meningioma may discuss these radiotherapy outcomes with their oncologists to weigh the benefits of post-surgical treatment against potential short-term side effects. This data provides a clearer roadmap for making informed decisions regarding secondary prevention strategies.
The takeaway
These findings suggest that active intervention post-surgery may significantly change the standard of care for meningioma patients. Healthcare providers and patients should consider the balance between short-term treatment side effects and the benefit of reducing long-term recurrence risks.
What happens next
Longer-term follow-up studies are expected to provide further data to confirm the initial findings regarding sustained disease-free survival.
Further reading
Learn more about the latest developments in this field in the Cancer section.
Live Poll
Would you follow new study findings to guide your personal medical treatment decisions?
